IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. & Encourag...
September 30 2016 - 11:04AM
Business Wire
Lundin Law PC (the “Firm”) announces the filing of a class
action lawsuit against Seres Therapeutics, Inc. (“Seres
Therapeutics” or the “Company”) (Nasdaq: MCRB) concerning possible
violations of federal securities laws between June 25, 2015 and
July 29, 2016 inclusive (the “Class Period”). Investors who
purchased or otherwise acquired shares during the Class Period
should contact the Firm in advance of the November 28, 2016 lead
plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esquire, of Lundin Law PC, at
888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
The complaint alleges that during the Class Period, Seres
Therapeutics made materially false and misleading statements and/or
failed to disclose material facts about its lead drug product
candidate SER-109, touting its potential and efficacy. On July 29,
2016, the Company announced that the Phase 2 clinical trial of
SER-109 did not meet its primary endpoint. When this information
was released to the public, shares of Seres Therapeutics lowered in
value, which caused investors harm.
Lundin Law PC was founded by Brian Lundin, a securities
litigator based in Los Angeles dedicated to upholding shareholders’
rights.
This press release may be considered Attorney Advertising in
certain jurisdictions under the applicable law and ethical
rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160930005557/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024